1. Mollugin may be a JAK2 inhibitor and inhibits LPS-induced inflammatory responses by blocking the activation of the JAK-STAT pathway.
2. Mollugin as a candidate for a chemotherapeutic agent in OSCCs via the upregulation of the HO-1 and Nrf2 pathways and the downregulation of NF- κ B.
3. Mollugin may be a novel therapeutic candidate for bone loss-associated disorders including osteoporosis, rheumatoid arthritis, and periodontitis.
4. Mollugin has anticancer efficacy, can modulate the HER2 pathway in HER2-overexpressing cancer cells with a potential role in the treatment and prevention of human breast and ovarian cancer with HER2 overexpression.
1. Cinobufotalin induces growth inhibition and apoptosis in cultured HCC cells through ceramide production, may be investigated as a novel anti-HCC agent.
2. Cinobufotalin can reverse the adriamycin-resistance in Raji/ADR cells and the expression of P-gp and MRP-1 proteins are down-regulated through the transcriptional pathway, is an effective reversal agent for the multidrug resistance of tumors.
1. Mahanine has a dose- and time-dependent anti-proliferative activity in acute lymphoid (MOLT-3) and chronic myeloid (K562) leukemic cell lines.
2. Mahanine has effects on the activation of the apoptotic pathway in human leukemia U937 cells, causes the mitochondrial membranes to lose their permeability, resulting in caspase-3 activation and apoptosis.
3. Mahanine can reverse an epigenetically silenced gene, RASSF1A in prostate cancer cells by inhibiting DNMT activity that in turn down-regulates a key cell cycle regulator, cyclin D1, is an encouraging therapeutic choice for advanced prostatic cancer.
4. Mahanine inhibited growth of PC3 and LNCaP prostate cancer cells in a dose and time-dependent manner, inhibits growth and induces apoptosis in both androgen-responsive, LNCaP and androgen-independent, PC3 cells by targeting cell survival pathway.
1. (-)-Syringaresinol inhibits the proliferation of human promyelocytic HL-60 cells through G(1) arrest and induction of apoptosis, may be a potential chemotherapeutic agent for the treatment of cancer.
1. Ingenol-3-angelate suppresses HIV infection of primary CD4+ T cells through down-modulation of cell surface expression of HIV co-receptors.
2. Ingenol 3-angelate activates a broad range of PKC isoforms and induces apoptosis in acute myeloid leukemia cells by activating the PKC isoform PKCdelta.
3. Ingenol-3-angelate shows anticancer activity, and P-gp-mediated absorptive transport, dermal penetration, and vascular damage contribute to the anticancer activity of ingenol-3-angelate in vivo.
4. Ingenol-3-angelate emerges as a unique local chemotherapeutic immunostimulatory debulking agent that could be used in conjunction with immunotherapies to promote regression of metastases.